TuisABCL • NASDAQ
add
AbCellera Biologics Inc
Vorige sluiting
$3,59
Dagwisseling
$3,36 - $3,62
Jaarwisseling
$1,89 - $6,52
Markkapitalisasie
1,09 mjd USD
Gemiddelde volume
4,47 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 44,85 m | 788,18% |
Bedryfskoste | 23,34 m | 8 713,28% |
Netto inkomste | -8,94 m | 73,85% |
Netto winsgrens | -19,94 | 97,06% |
Wins per aandeel | -0,03 | 75,00% |
EBITDA | -22,46 m | 13,76% |
Effektiewe belastingkoers | 54,13% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 533,83 m | -14,67% |
Totale bates | 1,36 mjd | -0,26% |
Totale aanspreeklikheid | 390,05 m | 28,11% |
Totale ekwiteit | 966,90 m | — |
Uitstaande aandele | 303,16 m | — |
Prys om te bespreek | 1,11 | — |
Opbrengs op bates | -5,27% | — |
Opbrengs op kapitaal | -6,45% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -8,94 m | 73,85% |
Kontant van bedrywe | -34,74 m | -334,29% |
Kontant van beleggings | 75,14 m | 110,45% |
Kontant van finansiering | 4,12 m | -0,65% |
Netto kontantverandering | 44,80 m | 50,92% |
Beskikbare kontantvloei | -6,97 m | 90,38% |
Meer oor
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia. Wikipedia
HUB
Gestig
2012
Hoofkwartier
Webwerf
Werknemers
562
